Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S3-E43.1 - Combination Agents for Fibrotic Regression
Description: This discussion begins with Naim offering an in-depth look into the mechanics of the recently published combination study. He explains that “semaglutide hits every point” in terms of effects on metabolic syndrome, cardiovascular outcomes, obesity and liver fat, but it has not yet been proven in monotherapy to regress fibrosis. Gilead Sciences had three agents whose potential anti-fibrotic effects the company wanted to explore fully, so Gilead and Novo Nordisk, which owns semaglutide, formed a partnership to develop these drugs.One agent, selonsertib, turned out to be ineffective, but the other two, the FXR agonist cilofexor and the...